Patents Assigned to Line 6 Biotechnology, Inc.
  • Methods and agents for the treatment of ocular disease
    Patent number: 11618782
    Abstract: This disclosure relates generally to methods and agents for treating an ocular disease or disorder. More particularly, the present disclosure relates to the use of CD14 antagonist antibodies for treating an ocular disease or disorder.
    Type: Grant
    Filed: February 23, 2022
    Date of Patent: April 4, 2023
    Assignee: Line 6 Biotechnology, Inc.
    Inventors: Brian W. Ziegelaar, Garry L. Redlich